‘The Reports of My Death Are Greatly Exaggerated’—Evaluating the Effect of Necrosis on MGMT Promoter Methylation Testing in High-Grade Glioma
Rattachement africain : au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
(1) Background: MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation remains an important predictive biomarker in high-grade gliomas (HGGs). The influence of necrosis on the fidelity of MGMT promoter (MGMTp) hypermethylation testing is currently unknown. Therefore, our study aims to evaluate the effect of varying degrees of necrosis on MGMTp status, as determined by pyrosequencing, in a series of primary and recurrent HGGs; (2) Methods: Within each case, the most viable blocks (assigned as ‘true’ MGMTp status) and the most necrotic block were determined by histopathology review. MGMTp status was determined by pyrosequencing. Comparisons of MGMTp status were made between the most viable and most necrotic blocks. (3) Results: 163 samples from 64 patients with HGGs were analyzed. MGMTp status was maintained in 84.6% of primary and 78.3% of recurrent HGGs between the most viable and necrotic blocks. A threshold of ≥60% tumor cellularity was established at which MGMTp status was unaltered, irrespective of the degree of necrosis. (4) Conclusions: MGMTp methylation status, as determined by pyrosequencing, does not appear to be influenced by necrosis in the majority of cases at a cellularity of at least 60%. Further investigation into the role of intratumoral heterogeneity on MGMTp status will increase our understanding of this predictive marker.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- ‘The Reports of My Death Are Greatly Exaggerated’—Evaluating the Effect of Necrosis on MGMT Promoter Methylation Testing in High-Grade Glioma
- Date Crossref
- 16/05/2024
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The University of Sydney NHMRC Clinical Trials Centre pays non établi dans la noticeUniversité ou école supérieure
-
Royal Prince Alfred Hospital Department of Neuropathology pays non établi dans la noticeÉtablissement de santé
-
Chris O’Brien Lifehouse pays non établi dans la noticeOrganisation à but non lucratif
-
Garvan Institute of Medical Research pays non établi dans la noticeOrganisation à but non lucratif
-
UNSW Sydney pays non établi dans la noticeUniversité ou école supérieure
-
The Kinghorn Cancer Centre pays non établi dans la noticeÉtablissement de santé
-
National Health and Medical Research Council pays non établi dans la noticeOrganisme public
-
Faculty of Medicine and Health pays non établi dans la noticeUniversité ou école supérieure
-
Department of Neurosurgery pays non établi dans la noticeInstitution
-
Department of Medical Oncology pays non établi dans la noticeInstitution
NHMRC Clinical Trials Centre — The University of Sydney, Department of Neuropathology — Royal Prince Alfred Hospital et Chris O’Brien Lifehouse, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.